Stocks rallied Monday, after a wobbly start, as investors were optimistic about the slew of earnings ahead.
Stocks rallied Monday, after a wobbly start, as techs dragged but investors were optimistic about the slew of earnings ahead.
In case you weren't aware, tomorrow is "World Osteoporosis Day" or WOD, for short, as the International Osteoporosis Foundation hilariously refers to it, but biotech Amgen won't be celebrating the occasion.
Stocks moved higher Monday, after a wobbly start, as techs dragged but investors were optimistic about the slew of earnings ahead.
Stocks continued to struggle on Friday. Could this be the beginning of a real market correction? Mike Rubino, president of Rubino Financial, and Paul Schatz, president of Heritage Capital, discussed how investors should position their portfolios for the end of the third quarter.
The drug biz is abuzz over social media. It's the new frontier. For a lot of PR and corporate communications teams it's all about new media and social media. Some biopharmas, big and small, now have directors of social media. Most are still trying to find their way, but the Food and Drug Administration may soon direct them.
Stocks hit new highs for 2009 after the weak dollar sent oil, gold and other commodities sharply higher.
When it rains, it pours. I mean, what a crazy Monday for deals and data in biopharma.
Stocks snapped their winning streak Thursday after soaring this week to new highs for the year.
Stocks got a quick pop Thursday from the Philadelphia Federal Reserve report on regional manufacturing but turned negative as General Electric dragged on the Dow.
Stocks got a quick pop Thursday from the Philadelphia Federal Reserve report on regional manufacturing but the gains began to fade as weakness nagged at the market. United Technologies, Bank of America and General Electric led the Dow.
Stock index futures showed relatively little reaction to the mixed economic reports out before the bell.
It seems three biotech stocks may be poised to break out. Find out which stocks to put on your radar right now.
Investors ought to get ready for a bull market, said Brian Belski, chief investment strategist at Oppenheimer & Co. and Art Nunes, market strategist at IMS Capital Management. They shared their take on the markets with investors.
Markets are likely to end the year higher and investors need some strong, blue-chip stocks in their portfolios, to counteract the volatility shown by cyclical shares, Bob Doll, global chief investment officer of equities at BlackRock, told CNBC Tuesday.
Stocks ended flat Tuesday as investors took a breather after Monday's blockbuster rally.
Stocks struggled to stay in positive territory for any length of time Tuesday as profit-taking after Monday's blockbuster rally overshadowed a fifth-straight rise in pending-home sales.
Stocks bounced back from a lower open Tuesday after a surprisingly sharp jump in pending-home sales.
Futures suggested stock would retreat Tuesday after a milestone session on Monday that sent the S&P over 1,000 for the first time since November.
Everyone’s talking about the July stock market rally. And, of course, you can’t overlook the outperformance of biotech—big and small.